Why Partner with Abogen?
-
1. Clinically validated platformCOVID-19 Safety and efficacy validated in 30,000+ subjects; EUA granted in Indonesia Beyond COVID-19 Promising safety and efficacy observed in human trials of internal immuno-oncology, autoimmune and infectious diseases programs
-
2. End-to-end capabilitiesAI AI-enhanced Design Engine for next-generation development of RNA and delivery technology RNA Proprietary mRNA/ circRNA/ saRNA platforms with fully automated, high-throughput synthesis capacities Delivery Proprietary and differentiated LNP technology for i.v./i.m./s.c./i.t. administration Formulation Liquid / Lyophilized / Frozen formulations (Lyo stable at 2-8°C for > 3 years) Manufacturing Scalable cGMP manufacturing
-
3. Patents and PublicationsPatents 150+ patents filed, 2/3 under the PCT Publications 18 research articles published in highly ranked journals
Our Partnering Interests
-
Asset Out-licensingWe are seeking partners to out-license the global or regional rights of our pipeline assets of infectious disease and cancer vaccines as well as a protein replacement therapy for autoimmune diseases.
-
Technology Out-licensingWe are seeking partners who are interested in licensing our proprietary mRNA/saRNA/circRNA technology, ionizable lipids and targeted LNPs.
-
Platform CollaborationsWe would like to collaborate with companies who are interested in utilizing our end-to-end technology platform to develop genetic medicines.
Contact us
- E-mail: Abogen.BD@abogenbio.com